OBJECTIVE To synthesize existing epidemiological data on cardiac dysfunction in HIV.
A bout 36.7 million people are infected with human immunodeficiency virus (HIV) globally. In the United States, it was estimated that 1.1 million people were living with HIV in 2016 (1) . The advent of highly active antiretroviral treatment (HAART) signified a defining moment for people living with HIV (PLHIV), with patients achieving longer life expectancy (2) . This shift to longer-term survival has led to increased prevalence of chronic diseases in PLHIV, including cardiovascular disease (CVD) (3) (4) (5) . A significant proportion of the CVD morbidity and mortality in PLHIV is due to HIV-associated cardiac dysfunction (3, 5) . Although the frequency of HIV-associated cardiomyopathy is thought to have decreased in the past decade, HIV patients still have a nearly 1.5-to 2-fold higher risk of clinical cardiac dysfunction (5-7). The proposed mechanisms include chronic inflammation, toxicity from certain HAART regimens, opportunistic infections, direct viral infection of the myocardium, nutritional disorders, and cardiac autoimmunity, among others (6, 8) .
Accruing epidemiological studies have reported on the frequency of cardiac dysfunction among PLHIV and the risk of cardiac dysfunction in relation to HIV infection; however, in these studies, the extent of cardiac dysfunction burden or risk is highly variable.
In addition, differences in burden or risk by type of We sought to perform a systematic review and meta-analysis of published literature on the frequency and relative risk of clinical heart failure (HF), LVSD, dilated cardiomyopathy (DCM), DD, pulmonary hypertension (PH), or RVSD among PLHIV.
METHODS
This study is reported according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) (9) guideline and is registered with
International Prospective Register of Systematic Reviews (PROSPERO). The Preferred Reporting Items for
Systematic Reviews and Meta-Analyses checklist is provided in Online Table 1 .
Three investigators (S.E., B.T.L., A.M.A.) independently performed the search, study selection, and data extraction. Complete details of the methods used in this meta-analysis are provided in the Online Methods. Briefly, we searched the electronic databases (Online Table 2 ) and the reference lists of relevant articles (2, 6, (10) (11) (12) (13) (14) .
We included studies of HIV-infected adults, reporting on the prevalence, incidence, or relative risk of HF, LVSD, DCM, DD, PH, or RVSD. Exclusion criteria were study size <50, studies including children <15 years of age, studies of HIV patients in which participants were selected based on suspected or known cardiac disease, and reports based on autopsy examination to diagnose heart disease. For the purpose of the meta-analysis, we pooled studies with a sufficiently similar definition of cardiac dysfunction. For LVSD, our main definition was ejection fraction <50% or fractional shortening <26%, but we also included other studies that were deemed to have used sufficiently close definition of LVSD. DCM was defined as presence of both LVSD and LV dilatation. For DD, we pooled studies that reported grades I to III DD separately from those that reported advanced (grades II to III) DD. For PH, we pooled studies that defined the outcome as echocardiogram-estimated pulmonary artery systolic pressure >35 mm Hg or >40 mm Hg.
RVSD was defined as RV systolic dysfunction (reduced RV function, RVEF <50% or RVEF <44%), RV dilatation, or both. We pooled the study-specific measures (i.e., prevalence, incidence, relative risk) with random-effects model meta-analysis using the DerSimonian and Laird's method (15) . The FreemanTukey single arcsine transformation helped limit the effects of extreme values on the pooled estimates (16) . We assessed the methodological quality of the individual studies using the Newcastle-Ottawa Scale (NOS) (17) . We assessed between-study heterogeneity using Q and I 2 statistics. We explored sources of heterogeneity using subgroup analyses and/or metaregression by the following a priori-defined studylevel characteristics: publication year, study region, study quality, study size, average age, proportion males, proportion with acquired immune deficiency syndrome (AIDS), average CD4 T-cell count, and proportion on antiretroviral therapy (ART). For subgroup analyses, publication year was divided "pre- 
Erqou et al. Table 5 for detail of scoring). The majority of the studies were graded as having low risk of bias, and >95% were graded as having low or moderate risk of bias. 
Cardiac Dysfunction in HIV F E B R U A R Y 2 0 1 9 : 9 8 -1 0 8 Figures 9 and 13 ). The imputation of frequency estimates to achieve funnel plot symmetry using the trim and fill method attenuated the results;
however, these imputed estimates were highly implausible (negative prevalence estimates), suggesting that the findings of funnel plot asymmetry were artifactual. Erqou et al.
Cardiac Dysfunction in HIV CI ¼ confidence interval; HF ¼ heart failure.
Cardiac Dysfunction in HIV reflection of the change in the standardized echocardiographic diagnostic criteria over the years (25) (26) (27) .
On the other hand, the finding of inverse association between average study CD4 T-cell count and prevalence of advanced DD is consistent with the report by Erqou et al.
Cardiac Dysfunction in HIV was only partially explained by available study level characteristics, which limits the generalizability of the findings. We used random-effects model metaanalysis to mitigate the effect of heterogeneity, which assumes that the underlying population parameter is different across studies and attempts to determine the mean of those parameters.
Another consequence of heterogeneity is that the meta-analysis yielded wider confidence intervals than would be expected for the size of the data. Erqou et al.
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